| Company Name | AbbVie Biopharmaceuticals GmbH Taiwan Branch |
|---|---|
| Protocol Number | P23-380 |
| Title of Study | A Multi-country, Post Marketing Observational Study of DME Patients with Suboptimal Response to anti-VEGF who are initiated with Dexamethasone intravitreal implant (DEX-I) |
| Primary Objective | To describe patient characteristics and assess anti-VEGF treatment patterns prior to DEX-I initiation |
| Number of Sites | 5 |
| Period of Study | From：01/2024 to：01/2027 |
| Number of Patients | 55人 |
| IRB Approval Date | National Taiwan University Hospital: 25 Jan 2024 China Medical University Hospital: 26 Jan 2024 Linkou Chang Gung Memorial Hospital: 23 Feb 2024 Far Eastern Memorial Hospital: 16 Mar 2024 Kaohsiung Veterans General Hospital: 20 Mar 2024 |
| Publication Plan / Date | 11/2027 |
